[443 Pages Report] The global depression treatment market is set to exceed US$ 10.1 Billion in 2022, and expand at a CAGR of 5.2% to reach US$ 16.8 Billion by 2032. According to a recent study, drugs are the leading segment in terms of products and accounted for over 99.4% of the demand share in 2021.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Depression Treatment Market Value 2021 | US$ 9.7 Billion |
| Market Value 2022 | US$ 10.1 Billion |
| Market Value 2032 | US$ 16.8 Billion |
| CAGR 2022 to 2032 | 5.2% |
| Market Share of Top 5 Countries | 58.9% |
The depression treatment market holds approximately 7.6% of the global behavioral health market worth US$ 128.2 Billion in 2021.
According to World Health Organization (WHO), the prevalence of mental health disorders and conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment.
Several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in the depression treatment market.
According to Future Market Insights (FMI), companies operating in the global depression treatment market are actively seeking to strengthen their position through mergers with established as well as emerging market players. For instance, in November 2020, Mylan completed a merger with Upjohn to form Viatris Company.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per FMI, the overall sales of depression treatment expanded at a CAGR of 3.4% from 2012 to 2021 owing to the increase in the prevalence of depression and anxiety disorders. Growth is also contributed to the growing need for antidepressants and therapies to treat mental conditions during the forecast period (2022 to 2032).
Depression treatments during a medical visit are time-consuming, and it is essential that people get treatment on time for depression. If conflicting demands continue to obstruct depression treatment, initiatives must ensure that patients with chronic physical difficulties receive high-quality mental healthcare in primary care.
According to a survey by the American Psychological Association (APA) in 2021, due to the pandemic, mental health issues are continuing to surge. Also, there has been a significant increase in demand for treatments for anxiety and depression compared to the last year.
Further, several new developments in antidepressants in the treatment of depression are being carried out in different drug classes, such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), antipsychotics, and others.
Recently, there has been a major shift in the market for depression disorders and other mental health disorder treatments. Numerous researchers and sponsors are developing novel drugs for the treatment of depression and getting approvals for them in different regions.
For instance, In September 2018, Alembic Pharmaceuticals received US FDA approval for its Desvenlafaxine ER capsules, 25 mg. A slew of these product launches and approvals of novel drugs and therapies in recent years is affecting the depression treatment market positively.
On the back of these aforementioned factors, sales in the depression treatment market are expected to increase at a CAGR of 5.2% from 2022 to 2032 globally.
Governments are trying to increase the funding for mental health services and the treatment of mental illness and depression disorders.
The need for good quality treatments, affordable healthcare policies, funding of government organizations, and interventions of healthcare organizations for mental health disorders treatments are some of the factors boosting the market.
Rising demand for improved brain and mental fitness is opening up new avenues for depression treatments since they improve glucose metabolism in the brain and lower the risk of mental disorders.
Improving healthcare infrastructure and increasing medical expenditure by the governments will support the development of expensive drugs and expensive medical devices. Hence, the demand for depression treatment is expected to further increase over the next few years.
Principal Consultant
The non-availability and the limited number of such well-trained specialists can create an adverse impact on the treatment of patients with depression. Due to these factors, the quality of services can get affected, hampering the growth of the depression treatment market.
The release of generic equivalents to drugs used in the treatment of depression will soon provide the impetus for great total market expansion, resulting in a variety of low-cost prescription options for consumers.
As pharmaceutical companies lose their patent protection, certain products will face generic competition for the first time. The companies that designed the original products will face more competition due to this. Thus, patent expiry problems will hinder the growth of the depression treatment market.
For instance, Lexapro, which is used in the treatment of anxiety and depression, had a patent issue that expired on March 14, 2012.
There is a social stigma associated with depression and other mental diseases. Self-stigmatization makes patients feel ashamed and isolated, and it may hinder them from receiving effective therapy. It could also potentially lead to somatization. difficulty to comprehend for those who have never experienced it can be mistaken as a sign of weakness.
Prevalence of Major Depressive Episodes (MDE) in the USA will Create Growth Prospects for Depression Treatment Market
The USA dominated the North American depression treatment market with a total share of about 92.8% in 2021 and is expected to experience the same growth throughout the forecast period owing to the rise in the prevalence of depressive disorders in the region.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had a major depressive episode with severe impairment.
Federal rules on drug launches and the availability of numerous branded formulations have a significant impact on market dynamics.
Increasing Number of Depressive Disorders in Germany will Drive the Demand for Depression Treatment
According to FMI, Germany is set to exhibit a lucrative CAGR of 5.3% in the Europe depression treatment market during the forecast period (2022 to 2032).
As per the Institute for Health Metrics and Evaluation, Germany is having 3.7% of prevalence rate for depression disorders. Hence, the rising prevalence of depressive disorders in Germany will boost the market growth during the forecast period.
Improved Medical Infrastructure in China to Augment the Growth in Depression Treatment Market
China held a 43.4% market share in the East Asia depression treatment market in 2021 and is projected to increase at a CAGR rate of 4.8% during the forecast period. Growth is associated with rising healthcare costs and rapidly improving medical infrastructure is expected to drive the market during the forecast years.
According to Global Health Expenditure Database, the level of per capita health spending in 2020 is expected to be over 5,112 yuan, up from roughly 4,669 yuan the previous year.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Drugs Contribute Over 99.4% of the Depression Treatment Market Sales
Based on products, the drugs segment will project a lucrative growth at a CAGR of 5.2% until 2032, with a market share of around 99.4% in 2021. Drugs are used as the first line of treatment during a depression treatment regime.
As compared to devices, drugs have a higher adoption rate and are cost-effective. TMS devices are commonly employed when other depression therapies have failed. In addition, the administration of drugs, which acts as antidepressants, improves the effectiveness of the treatment of depression without increasing the risk of clinically significant safety events, which makes it the most lucrative in depression treatment.
Rising Prevalence of Major Depression Episodes to Improve Depression Treatment Market Growth
Major depression held a revenue share of 53.5% in 2021 with a CAGR rate of 5.3%. The high market share is because major depression is highly being observed in the population over the world, which includes the symptoms such as anxiety, stress, mental illness, and others.
The high prevalence of major depression in the world is expected to contribute to enhancing market growth from 2022 to 2032.
Hospitals, in terms of distribution channels, led the depression treatment market with a 25.8% market share in 2021. During depression treatment, patients prefer to be admitted to the hospital to seek treatment.
The availability of highly skilled medical professionals that provide better treatment experience also contributed to the high market share during the coming years.
Key players in the depression treatment market are focusing their efforts on acquisitions and expansion to move on with the development of a unique, first-in-class asset for the treatment of cognitive impairment caused by neuropsychiatric and neurodegenerative illnesses.
Given below are a few examples of the key strategies followed by the manufacturers:
| Attribute | Details |
|---|---|
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC countries, Turkey, South Africa, and North Africa. |
| Key Market Segments Covered | Products, Diseases, Distribution Channels, and Regions |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global depression treatment market was worth US$ 9.7 Billion in 2021 and is set to expand 1.7X over the next ten years.
The depression treatment market is expected to reach US$ 16.8 Billion by the end of 2032, with sales revenue expected to register a growth of 5.2% CAGR.
Adoption of different key strategies by market players and mergers and acquisitions by manufacturers are some of the key trends in the depression treatment market.
The USA, Germany, UK, India and China are expected to drive demand for the depression treatment industry.
North America is of the leading depression treatment market, with a market share of 40.3% in 2021 in the global market.
Demand for depression treatment in Europe is expected to register a growth of 5.2% CAGR over the next ten years.
From 2012 to 2021, the market for depression treatment expanded at the rate of 3.4%.
BrainsWay Ltd., Neuronetics, Inc., and Novartis are the Top 3 key players in the depression treatment market.
1. Executive Summary | Depression Treatment Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions & Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation / Development Trends 4. Key Success Factors 4.1. Disease Epidemiology, By Region 4.2. Drug Adoption / Usage Analysis 4.3. New Drug Approvals & Launches 4.4. Key Promotional Strategies by Market Players 4.5. Pipeline Analysis 4.6. Regulatory Scenario 4.7. PESTLE Analysis 4.8. Porter’s Analysis 4.9. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Market Outlook 5.1.3. Global Mental Health Disorders Market Outlook 5.1.4. Global Pharmaceutical Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Product Adoption Rate and Demand 5.2.3. Increasing burden of mental illnesses 5.2.4. Availability of various therapies 5.2.5. COVID-19 impact 5.2.6. Technological Advancements in Equipment 5.2.7. Increasing Demand for Depression Disorders Treatment 5.2.8. New Product Launches 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID-19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. COVID-19 and Impact Analysis 6.4. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Product Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Product Type, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032 8.3.1. Drugs 8.3.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 8.3.1.1.1. Citalopram 8.3.1.1.2. Escitalopram 8.3.1.1.3. Fluoxetine 8.3.1.1.4. Fluvoxamine 8.3.1.1.5. Paroxetine 8.3.1.1.6. Sertraline 8.3.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs) 8.3.1.2.1. Desvenlafaxine succinate 8.3.1.2.2. Duloxetine 8.3.1.2.3. Levomilnacipran 8.3.1.2.4. Venlafaxine 8.3.1.3. Bupropion 8.3.1.4. Mirtazapine 8.3.1.5. Monoamine oxidase inhibitors (MAOIs) 8.3.1.5.1. Phenelzine 8.3.1.5.2. Tranylcypromine 8.3.1.6. Antipsychotics 8.3.1.6.1. Lithium carbonate 8.3.1.6.2. Aripiprazole 8.3.1.6.3. Brexipiprazole 8.3.1.6.4. Quetiapine 8.3.1.7. Trazodone 8.3.1.8. Others 8.3.2. TMS Devices 8.3.2.1. rTMS Devices 8.3.2.2. dTMS Devices 8.4. Market Attractiveness Analysis By Disease Type 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Disease Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Disease Type, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032 9.3.1. Major Depression 9.3.2. Persistent Depressive Disorder 9.3.3. Bipolar Disorder 9.3.4. Seasonal Affective Disorder (SAD) 9.3.5. Postpartum Depression 9.3.6. Premenstrual Dysphoric Disorder (PDD) 9.3.7. Situational Depression 9.3.8. Atypical Depression 9.3.9. Treatment-Resistant Depression 9.4. Market Attractiveness Analysis By Disease Type 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel 2022 to 2032 10.3.1. Hospitals 10.3.2. Retail Pharmacies 10.3.3. Drug Stores 10.3.4. e-commerce 10.3.5. Specialty Clinics 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis, By Region, 2012 to 2021 11.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. United States of America 12.3.1.2. Canada 12.3.2. By Product Type 12.3.3. By Disease Type 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Product Type 12.4.3. By Disease Type 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country-Level Analysis & Forecast 12.8.1. USA Market 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Product Type 12.8.1.2.2. By Disease Type 12.8.1.2.3. By Distribution Channel 12.8.2. Canada Market 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Product Type 12.8.2.2.2. By Disease Type 12.8.2.2.3. By Distribution Channel 13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Product Type 13.3.3. By Disease Type 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Product Type 13.4.3. By Disease Type 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. Brazil Market 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Product Type 13.8.1.2.2. By Disease Type 13.8.1.2.3. By Distribution Channel 13.8.2. Mexico Market 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Product Type 13.8.2.2.2. By Disease Type 13.8.2.2.3. By Distribution Channel 13.8.3. Argentina Market 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Product Type 13.8.3.2.2. By Disease Type 13.8.3.2.3. By Distribution Channel 14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. United Kingdom 14.3.1.2. Germany 14.3.1.3. Italy 14.3.1.4. France 14.3.1.5. Spain 14.3.1.6. Russia 14.3.1.7. BENELUX 14.3.1.8. Rest of Europe 14.3.2. By Product Type 14.3.3. By Disease Type 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product Type 14.4.3. By Disease Type 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. UK Market 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Product Type 14.8.1.2.2. By Disease Type 14.8.1.2.3. By Distribution Channel 14.8.2. Germany Market 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Product Type 14.8.2.2.2. By Disease Type 14.8.2.2.3. By Distribution Channel 14.8.3. Italy Market 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Product Type 14.8.3.2.2. By Disease Type 14.8.3.2.3. By Distribution Channel 14.8.4. France Market 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Product Type 14.8.4.2.2. By Disease Type 14.8.4.2.3. By Distribution Channel 14.8.5. Spain Market 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Product Type 14.8.5.2.2. By Disease Type 14.8.5.2.3. By Distribution Channel 14.8.6. Russia Market 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Product Type 14.8.6.2.2. By Disease Type 14.8.6.2.3. By Distribution Channel 14.8.7. BENELUX Market 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Disease Type 14.8.7.2.2. By Product Type 14.8.7.2.3. By Distribution Channel 15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Product Type 15.3.3. By Disease Type 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product Type 15.4.3. By Disease Type 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. India Market 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product Type 15.8.1.2.2. By Disease Type 15.8.1.2.3. By Distribution Channel 15.8.2. Thailand Market 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Product Type 15.8.2.2.2. By Disease Type 15.8.2.2.3. By Distribution Channel 15.8.3. Indonesia Market 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Product Type 15.8.3.2.2. By Disease Type 15.8.3.2.3. By Distribution Channel 15.8.4. Malaysia Market 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Product Type 15.8.4.2.2. By Disease Type 15.8.4.2.3. By Distribution Channel 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 16.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Product Type 16.3.3. By Disease Type 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product Type 16.4.3. By Disease Type 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Product Type 16.8.1.2.2. By Disease Type 16.8.1.2.3. By Distribution Channel 16.8.2. Japan Market 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Product Type 16.8.2.2.2. By Disease Type 16.8.2.2.3. By Distribution Channel 16.8.3. South Korea Market 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Product Type 16.8.3.2.2. By Disease Type 16.8.3.2.3. By Distribution Channel 17. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 17.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Product Type 17.3.3. By Disease Type 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product Type 17.4.3. By Disease Type 17.4.4. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. Australia Market 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Product Type 17.8.1.2.2. By Disease Type 17.8.1.2.3. By Distribution Channel 17.8.2. New Zealand Market 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Product Type 17.8.2.2.2. By Disease Type 17.8.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 18.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. Turkey 18.3.1.2. GCC Countries 18.3.1.3. North Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Product Type 18.3.3. By Disease Type 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product Type 18.4.3. By Disease Type 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. Turkey Market 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Product Type 18.8.1.2.2. By Disease Type 18.8.1.2.3. By Distribution Channel 18.8.2. GCC Countries Market 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Product Type 18.8.2.2.2. By Disease Type 18.8.2.2.3. By Distribution Channel 18.8.3. North Africa Market 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Product Type 18.8.3.2.2. By Disease Type 18.8.3.2.3. By Distribution Channel 18.8.4. South Africa Market 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Product Type 18.8.4.2.2. By Disease Type 18.8.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Technology Foot-Print, By Competition 20.3. Competition Benchmarking 20.4. Competition Deep Dive 20.4.1. Viatris (Mylan Pharmaceuticals Inc.) 20.4.1.1. Overview 20.4.1.2. Product Portfolio 20.4.1.3. Key Financials 20.4.1.4. SWOT Analysis 20.4.1.5. Sales Footprint 20.4.1.6. Strategy Overview 20.4.1.7. Key Developments 20.4.2. Sunovian Pharmaceuticals 20.4.2.1. Overview 20.4.2.2. Product Portfolio 20.4.2.3. Key Financials 20.4.2.4. SWOT Analysis 20.4.2.5. Sales Footprint 20.4.2.6. Strategy Overview 20.4.2.7. Key Developments 20.4.3. AbbVie Inc (Allergan, Inc.) 20.4.3.1. Overview 20.4.3.2. Product Portfolio 20.4.3.3. Key Financials 20.4.3.4. SWOT Analysis 20.4.3.5. Sales Footprint 20.4.3.6. Strategy Overview 20.4.3.7. Key Developments 20.4.4. Jubilant Generics Limited 20.4.4.1. Overview 20.4.4.2. Product Portfolio 20.4.4.3. Key Financials 20.4.4.4. SWOT Analysis 20.4.4.5. Sales Footprint 20.4.4.6. Strategy Overview 20.4.4.7. Key Developments 20.4.5. Sanis Health Inc 20.4.5.1. Overview 20.4.5.2. Product Portfolio 20.4.5.3. Key Financials 20.4.5.4. SWOT Analysis 20.4.5.5. Sales Footprint 20.4.5.6. Strategy Overview 20.4.5.7. Key Developments 20.4.6. Abbott Laboratories 20.4.6.1. Overview 20.4.6.2. Product Portfolio 20.4.6.3. Key Financials 20.4.6.4. SWOT Analysis 20.4.6.5. Sales Footprint 20.4.6.6. Strategy Overview 20.4.6.7. Key Developments 20.4.7. Aurobindo Pharma 20.4.7.1. Overview 20.4.7.2. Product Portfolio 20.4.7.3. Key Financials 20.4.7.4. SWOT Analysis 20.4.7.5. Sales Footprint 20.4.7.6. Strategy Overview 20.4.7.7. Key Developments 20.4.8. Torrent Pharmaceuticals 20.4.8.1. Overview 20.4.8.2. Product Portfolio 20.4.8.3. Key Financials 20.4.8.4. SWOT Analysis 20.4.8.5. Sales Footprint 20.4.8.6. Strategy Overview 20.4.8.7. Key Developments 20.4.9. Teva Pharmaceuticals 20.4.9.1. Overview 20.4.9.2. Product Portfolio 20.4.9.3. Key Financials 20.4.9.4. SWOT Analysis 20.4.9.5. Sales Footprint 20.4.9.6. Strategy Overview 20.4.9.7. Key Developments 20.4.10. Sun Pharmaceuticals 20.4.10.1. Overview 20.4.10.2. Product Portfolio 20.4.10.3. Key Financials 20.4.10.4. SWOT Analysis 20.4.10.5. Sales Footprint 20.4.10.6. Strategy Overview 20.4.10.7. Key Developments 20.4.11. (Apotex Holdings, Inc.) Apotex Corporation 20.4.11.1. Overview 20.4.11.2. Product Portfolio 20.4.11.3. Key Financials 20.4.11.4. SWOT Analysis 20.4.11.5. Sales Footprint 20.4.11.6. Strategy Overview 20.4.11.7. Key Developments 20.4.12. Alembic Pharmaceuticals Limited 20.4.12.1. Overview 20.4.12.2. Product Portfolio 20.4.12.3. Key Financials 20.4.12.4. SWOT Analysis 20.4.12.5. Sales Footprint 20.4.12.6. Strategy Overview 20.4.12.7. Key Developments 20.4.13. Pfizer Inc 20.4.13.1. Overview 20.4.13.2. Product Portfolio 20.4.13.3. Key Financials 20.4.13.4. SWOT Analysis 20.4.13.5. Sales Footprint 20.4.13.6. Strategy Overview 20.4.13.7. Key Developments 20.4.14. Cardinal Health 20.4.14.1. Overview 20.4.14.2. Product Portfolio 20.4.14.3. Key Financials 20.4.14.4. SWOT Analysis 20.4.14.5. Sales Footprint 20.4.14.6. Strategy Overview 20.4.14.7. Key Developments 20.4.15. Hikma Pharmaceuticals 20.4.15.1. Overview 20.4.15.2. Product Portfolio 20.4.15.3. Key Financials 20.4.15.4. SWOT Analysis 20.4.15.5. Sales Footprint 20.4.15.6. Strategy Overview 20.4.15.7. Key Developments 20.4.16. Zydus Lifesciences (Cadila) 20.4.16.1. Overview 20.4.16.2. Product Portfolio 20.4.16.3. Key Financials 20.4.16.4. SWOT Analysis 20.4.16.5. Sales Footprint 20.4.16.6. Strategy Overview 20.4.16.7. Key Developments 20.4.17. Cipla Ltd 20.4.17.1. Overview 20.4.17.2. Product Portfolio 20.4.17.3. Key Financials 20.4.17.4. SWOT Analysis 20.4.17.5. Sales Footprint 20.4.17.6. Strategy Overview 20.4.17.7. Key Developments 20.4.18. Dr. Reddy's Laboratories 20.4.18.1. Overview 20.4.18.2. Product Portfolio 20.4.18.3. Key Financials 20.4.18.4. SWOT Analysis 20.4.18.5. Sales Footprint 20.4.18.6. Strategy Overview 20.4.18.7. Key Developments 20.4.19. Merck & Co. 20.4.19.1. Overview 20.4.19.2. Product Portfolio 20.4.19.3. Key Financials 20.4.19.4. SWOT Analysis 20.4.19.5. Sales Footprint 20.4.19.6. Strategy Overview 20.4.19.7. Key Developments 20.4.20. Eli Lily & Co 20.4.20.1. Overview 20.4.20.2. Product Portfolio 20.4.20.3. Key Financials 20.4.20.4. SWOT Analysis 20.4.20.5. Sales Footprint 20.4.20.6. Strategy Overview 20.4.20.7. Key Developments 20.4.21. GlaxoSmithKline 20.4.21.1. Overview 20.4.21.2. Product Portfolio 20.4.21.3. Key Financials 20.4.21.4. SWOT Analysis 20.4.21.5. Sales Footprint 20.4.21.6. Strategy Overview 20.4.21.7. Key Developments 20.4.22. Takeda Pharmaceuticals 20.4.22.1. Overview 20.4.22.2. Product Portfolio 20.4.22.3. Key Financials 20.4.22.4. SWOT Analysis 20.4.22.5. Sales Footprint 20.4.22.6. Strategy Overview 20.4.22.7. Key Developments 20.4.23. BrainsWay Ltd. 20.4.23.1. Overview 20.4.23.2. Product Portfolio 20.4.23.3. Key Financials 20.4.23.4. SWOT Analysis 20.4.23.5. Sales Footprint 20.4.23.6. Strategy Overview 20.4.23.7. Key Developments 20.4.24. Nexstim Plc 20.4.24.1. Overview 20.4.24.2. Product Portfolio 20.4.24.3. Key Financials 20.4.24.4. SWOT Analysis 20.4.24.5. Sales Footprint 20.4.24.6. Strategy Overview 20.4.24.7. Key Developments 20.4.25. Magstim Ltd. 20.4.25.1. Overview 20.4.25.2. Product Portfolio 20.4.25.3. Key Financials 20.4.25.4. SWOT Analysis 20.4.25.5. Sales Footprint 20.4.25.6. Strategy Overview 20.4.25.7. Key Developments 20.4.26. Neuronetics, Inc. 20.4.26.1. Overview 20.4.26.2. Product Portfolio 20.4.26.3. Key Financials 20.4.26.4. SWOT Analysis 20.4.26.5. Sales Footprint 20.4.26.6. Strategy Overview 20.4.26.7. Key Developments 20.4.27. Salience TMS Neuro Solutions 20.4.27.1. Overview 20.4.27.2. Product Portfolio 20.4.27.3. Key Financials 20.4.27.4. SWOT Analysis 20.4.27.5. Sales Footprint 20.4.27.6. Strategy Overview 20.4.27.7. Key Developments 20.4.28. MagVenture 20.4.28.1. Overview 20.4.28.2. Product Portfolio 20.4.28.3. Key Financials 20.4.28.4. SWOT Analysis 20.4.28.5. Sales Footprint 20.4.28.6. Strategy Overview 20.4.28.7. Key Developments 20.4.29. MAG & More GmbH 20.4.29.1. Overview 20.4.29.2. Product Portfolio 20.4.29.3. Key Financials 20.4.29.4. SWOT Analysis 20.4.29.5. Sales Footprint 20.4.29.6. Strategy Overview 20.4.29.7. Key Developments 20.4.30. Neurosoft, Ltd. 20.4.30.1. Overview 20.4.30.2. Product Portfolio 20.4.30.3. Key Financials 20.4.30.4. SWOT Analysis 20.4.30.5. Sales Footprint 20.4.30.6. Strategy Overview 20.4.30.7. Key Developments 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Depression Treatment Market
